A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects

被引：0
|
作者：
Ippei Ikushima
Lene Jensen
Anne Flint
Tomoyuki Nishida
Jeppe Zacho
Shin Irie
机构：
[1] LTA Sumida Hospital,
[2] Novo Nordisk A/S,undefined
[3] Novo Nordisk Pharma Ltd,undefined
[4] SOUSEIKAI Global Clinical Research Center,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
GLP-1 receptor agonist; Japanese subjects; Pharmacodynamics; Pharmacokinetics; Semaglutide; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：531 / 544
页数：13
相关论文
共 50 条
  • [21] Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects
    Yamahira, Naomi
    Frost, Charles
    Fukase, Hiroyuki
    Yu, Zhigang
    Wang, Jessie
    Pursley, Janice
    LaCreta, Frank
    Hiraoka, Masaki
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (07) : 564 - 573
  • [22] Pharmacokinetics and Tolerability of Almorexant in Japanese and Caucasian Healthy Male Subjects
    Hoch, Matthias
    Hoever, Petra
    Alessi, Federica
    Marjason, Joanne
    Dingemanse, Jasper
    PHARMACOLOGY, 2011, 88 (3-4) : 121 - 126
  • [23] A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
    Xie, Panpan
    Abildlund, Morten T.
    Baekdal, Tine A.
    He, Xuemei
    Lyauk, Yassine K.
    Patted, Usha Rani H.
    Ning, Zu
    Shi, Aixin
    DIABETES OBESITY & METABOLISM, 2024, 26 (08): : 3068 - 3077
  • [24] A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects
    Harada-Shiba, Mariko
    Ali, Shazia
    Gipe, Daniel A.
    Gasparino, Evelyn
    Son, Vladimir
    Zhang, Yi
    Pordy, Robert
    Catapano, Alberico L.
    ATHEROSCLEROSIS, 2020, 314 : 33 - 40
  • [25] Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: Results of a randomized, double-blind, placebo-controlled trial
    Vincent, JL
    Spapen, HDMH
    Creteur, J
    Piagnerelli, M
    Hubloue, I
    Diltoer, M
    Roman, A
    Stevens, E
    Vercammen, E
    Beaver, JS
    CRITICAL CARE MEDICINE, 2006, 34 (06) : 1661 - 1667
  • [26] PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PONESIMOD IN JAPANESE AND CAUCASIAN HEALTHY SUBJECTS
    Reyes, M.
    Brossard, P.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S93 - S94
  • [27] The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects.
    Small, D. S.
    Kothare, P. A.
    Yuen, E. S.
    Li, Y. G.
    Winters, K. J.
    Farid, N. A.
    Ni, L.
    Salazar, D. E.
    Payne, C. D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S56 - S57
  • [28] Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched Caucasian subjects
    Rocha, J. F.
    Falcao, A.
    Lopes, N.
    Santos, A.
    Nunes, T.
    Soares-da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 362 - 362
  • [29] Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
    Buse, John B.
    Christensen, Helene Nordahl
    Harty, Brian J.
    Mitchell, Julie
    Soule, Benjamin P.
    Zacherle, Emily
    Cziraky, Mark
    Willey, Vincent J.
    BMJ OPEN DIABETES RESEARCH & CARE, 2023, 11 (03)
  • [30] Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched Caucasian subjects
    Rocha, J. F.
    Falcao, A.
    Lopes, N.
    Santos, A.
    Nunes, T.
    Soares-da-Silva, P.
    JOURNAL OF NEUROLOGY, 2014, 261 : S243 - S243
12345